Status: Not yet recruiting
Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
Subjects will receive zolbetuximab with either CAPOX every 3 weeks or mFOLFOX6 every 2 weeks. The chemotherapy regimen chosen, mFOLFOX6 or CAPOX is per the treating investigator discretion and subject preference. Study treatment will continue for a maximum of 2 years, or until disease progression per RECIST 1.1, intolerable side effects, or investigator/subject preference. Disease evaluation will occur every 8 to 9 weeks.
Participants needed: 32
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Midhun MallaUpdated: Jul 24, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years at the time of informed consent. [+23]
Receipt of 5-fluorouracil or capecitabine in the adjuvant setting within 6 month... [+15]